Tarsus Pharmaceuticals, Inc. TARS Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating income?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating income of -$6.12M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s operating income changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating income increased by 76.7% year-over-year, from -$26.28M to -$6.12M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating income?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s operating income has grown at a 55.4% compound annual growth rate (CAGR), from -$12.16M to -$70.97M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.